BioLargo (NASDAQ:BLGO – Get Free Report) and Standard Lithium (NYSE:SLI – Get Free Report) are both small-cap construction companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.
Risk & Volatility
BioLargo has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Standard Lithium has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.
Profitability
This table compares BioLargo and Standard Lithium’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLargo | -11.45% | -39.90% | -22.06% |
| Standard Lithium | N/A | -11.52% | -10.25% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLargo | 0 | 0 | 0 | 0 | 0.00 |
| Standard Lithium | 0 | 0 | 2 | 0 | 3.00 |
Standard Lithium has a consensus target price of $3.95, suggesting a potential upside of 143.83%. Given Standard Lithium’s stronger consensus rating and higher possible upside, analysts plainly believe Standard Lithium is more favorable than BioLargo.
Valuation & Earnings
This table compares BioLargo and Standard Lithium”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLargo | $12.23 million | 6.21 | -$3.50 million | ($0.01) | -25.22 |
| Standard Lithium | N/A | N/A | $108.82 million | $0.59 | 2.75 |
Standard Lithium has lower revenue, but higher earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Standard Lithium, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 16.8% of Standard Lithium shares are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 3.7% of Standard Lithium shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Standard Lithium beats BioLargo on 11 of the 13 factors compared between the two stocks.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
About Standard Lithium
Standard Lithium Ltd. explores for, develops, and processes lithium brine properties in the United States. Its flagship project is the Lanxess project with area of approximately 150,000 acres located in southern Arkansas. The company was formerly known as Patriot Petroleum Corp. and changed its name to Standard Lithium Ltd. in December 2016. Standard Lithium Ltd. was incorporated in 1998 and is headquartered in Vancouver, Canada.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.
